ArticleNano letters2025
The RNA Landscape of In Vivo-Assembled MS2 Virus-Like Particles as mRNA Carriers Reveals RNA Contamination from Host Viruses.
Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virus-like particles (VLPs) are attractive systems for packaging and delivering therapeutic RNA molecules in vaccine development, protein replacement therapy, and gene editing. Different VLPs carrying target functional RNA have been biosynthesized and demonstrated for biomedical purposes. However, little attention has been paid to what other types of RNA, besides the target RNA, are encapsulated into VLPs, leading to a lack of knowledge of the landscape of RNA cargoes. In this work, we engineered the widely used MS2 VLPs to encapsulate a model cargo mRNA in yeast, with the packaging efficiency and specificity being quantitatively tuned by the copy number of packaging signals. Transcriptome sequencing of the RNA in the VLPs revealed RNA contamination from the hosts and host viruses. This study highlights the necessity of precise VLP and cargo design and a clear background of production hosts to ensure specificity and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.